Joint Symposium 16
Oncology & Theranostics Committee / European Society for Medical Oncology (ESMO)
Accessible on-demand at any time

Session Title
Combination Treatments - What can Radioligand Therapy be Combined with?

Chairperson
Ken Herrmann (Essen, Germany)

Programme
29 min  Ursula Vogl (Bellinzona, Switzerland / ESMO): Combination Treatment in Prostate Cancer
29 min  Marianne Pavel (Erlangen, Germany): Combination Treatment in NETs
29 min  Johannes Czernin (Los Angeles, United States of America): Preclinical Considerations for Combination Treatment
3 min  Session Summary by Chairperson

Educational Objectives
1. Understanding the potential upside of combination therapy including RLT
2. Discussion of early experiences in combining RLT with other therapies in NETs and prostate cancer
3. Learning preclinical concepts of investigating combination treatment involving RLT

Summary
Radioligand therapy (RLT) is one of the most exciting developments in nuclear medicine. Despite the intriguing results of NETTER-1 and the positive VISION study a significant proportion of patients do not or only temporarily benefit from RLT. The rationale of combination treatment, an established concept in oncology, seems to be the consistent next step in establishing RLT in clinical care. This session is dedicated to explore if and how RLT can be combined with in regards to prostate cancer and NETs. Moreover, there will be a dedicated talk to learn also about preclinical considerations for combination treatment.

Key Words
RLT – combination therapy – NETs – prostate cancer